​2001-2007- Ph.D. (University of Colorado Health Sciences Center, Denver, CO)

1998-2001- M.S. (Peking University, Beijing, China)

1992-1996- B.S. (East China University of Science and Technology, Shanghai, China)

Professional Appointments:

•  (AY2018/2019) Duke-NUS Medial School: Teaching Medical Student Courses (AY2018/2019)--Molecules, Cells and Tissues
• 2019.11-present     Principal Investigator/Associate Professor; Division of Cellular and Molecular Research, National Cancer Center Singapore; Cancer and Stem Cell Program, Duke-NUS Medical School
• 2018-present: NCCS RBC Committee
• 2016-present: NCCS Research Space Committee
• 2014.11-2019.10    Principal Investigator/Assistant Professor; Division of Cellular and Molecular Research, National Cancer Center Singapore; Cancer and Stem Cell Program, Duke-NUS Medical School
• 2014.1-2014.10      Instructor, Department of Pathology & Immunology, Washington University at St. Louis and Howard Hughes Medical Institute, St. Louis, MO, USA
• 2008.2-2013.12      Post-doctoral Research Fellow, Department of Pathology & Immunology, Washington University in St. Louis and Howard Hughes Medical Institute, St. Louis, MO, USA
• 2007.8-2008.1        Transitional Post-doctoral Research Fellow, Integrated Department of Immunology, University of Colorado Health Sciences Center/National Jewish Medical and Research Center, Denver, CO, USA
• 2001.9-2007.7        Ph.D. Candidate Research Assistant, Integrated Department of Immunology, University of Colorado Health Sciences Center/National Jewish Medical and Research Center, Denver, CO, USA
  1998.9-2001.8        Graduate Student Research Assistant, Department of Cell Biology & Genetics, Peking University, Beijing, China
• 1996.7-1998.8        Teaching & Research Assistant, Department of Biotechnology, Suzhou Medical College, Suzhou, China
  

Grants awarded:

• ​​Characterize the RAF complex under pathological conditions and develop novel therapies for hyperactive Ras/RAF/MEK/ERK signalling-driven cancers. (Aug-2019 to Jan-2023)
  
• Develop novel approaches to overcome the drug resistance in the targeted cancer therapy with RAF inhibitors. (Apr-2019 Mar-2021)

Teaching Medical Student Courses:

• Molecules, Cells and Tissues - Duke-NUS Medical School (AY2018/2019)

Institutional Services:

• Member - NCCS Research Space Committee (2016~present)
• Member - NCCS RBC Committee (2018~present)
  

• 2005-2006              Colorado Cancer League Scholarship, USA
• 2002-2005              Cancer Research Institute Scholarship, USA

• ​The regulatory mechanism of RAF family kinases and other oncogenic protein kinases under normal/pathological conditions
• Molecular basis that underlie intrinsic and acquired resistance of kinase inhibitors in clinic treatment of cancers
• The development of novel kinase inhibitors

​1. Yap J, Yuan J, Tee ZH, Huang X, Ng WH, Hu J. Characterize Disease-Related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods. J. Vis. Exp. 2019, e59795.

2. Yuan J, Ng WH, Lam P, Wang Y, Xia H, Yap JJ, Guan SP, Lee A, Wang M, Baccarini M, and Hu J. The Dimer-dependent Catalytic Activity of RAF Family Kinases Is Revealed Through Characterizing Their Oncogenic Mutants. Oncogene. 2018; 37(43):5719-5734.

3. Yuan J, Ng WH, Tian Z, Yap JJ, Baccarini M, Chen Z and Hu J. Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis. Sci. Signal. 2018; 11(554): eaar6795.

4. Yuan J, Ng WH, Yap JJ, Chia B, Huang X, Wang M and Hu J. The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking the phospho-Ser-621 in the carboxyl-terminus of CRAF. J. Biol. Chem. 2018; 293(37):14276-14284.

5. Hu J, Ahuja LG, Meharena HS, Kannan N, Kornev AP, Taylor SS, Shaw AS. Kinase Regulation by Hydrophobic Spine Assembly in Cancer. Mol. Cell. Biol. 2015; 35(1): 264-276.

6. Wang X*, Boyken SE*, Hu J, Xu X, Rimer RP, Shea MA, Shaw AS, Andreotti AH and Huang YH. Calmodulin and PI(3,4,5)P₃ cooperatively bind to the Itk pleckstrin homology domain to promote efficient calcium signaling and IL-17A production. Sci. Signal. 2014; 7(337), ra74.

7. Shaw AS, Kornev AP, Hu J, Ahuja LG, Taylor SS. Kinases and Pseudokinases: Lessons from RAF. Mol. Cell. Biol. 2014; 34(9): 1538-46. (Review) 

8. Hu J*, Oda SK*, Donovan EE, Shotts K, Strauch P, Pujanaushi LM, Victorino F, Al-Shami A, Fujiwara Y, Tigyi G, Oravecz T, Pelanda R and Torres RM. Lysophosphatidic acid (LPA) receptor 5 inhibits B Cell antigen receptor signaling and antibody response. J. Immunol. 2014; 193(1): 85-95.

9. Hu J, Stites EC, Yu H, Germino E, Meharena HS, Stork PJS, Kornev AP, Taylor SS, Shaw AS. Allosteric activation of functionally asymmetric Raf kinase dimers. Cell. 2013; 154(5): 1036-1046.

10. Hu J, Yu H, Kornev AP, Zhao J, Filbert EL, Taylor SS, Shaw AS. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. PNAS. 2011; 108(15): 6067-72.